Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | DPYD | Q12882 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28250779 | 0.98 | GAA (0.48) | GAADPYDMAPTALDH1A1LMNA | |
| SCHEMBL6684769 | 0.78 | ATAD2 (0.50) | GAADPYDMAPTALDH1A1LMNA | |
| SCHEMBL5751524 | 0.78 | DPYD (0.45) | GAADPYDMAPTALDH1A1LMNA | |
| Thymine SCHEMBL8727441 | 0.72 | ATAD2 (0.79) | GAADPYDMAPTALDH1A1LMNA | |
| SCHEMBL27396242 | 0.70 | MEN1 (0.34) | GAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL190171 | 0.69 | LMNA (0.49) | GAADPYDMAPTALDH1A1LMNA | |
| SCHEMBL48366 | 0.67 | — | — | |
| SCHEMBL5801644 | 0.66 | ALDH1A1 (0.64) | GAADPYDMAPTALDH1A1LMNA | |
| SCHEMBL11414580 | 0.65 | LMNA (0.33) | LMNATSHRSMN1; SMN2 | |
| SCHEMBL6573722 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107354-A1 | METHODS FOR ENRICHING FOR METHYLATED NUCLEIC ACID MOLECULES | HARBINGER HEALTH, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260117312-A1 | METHODS FOR IDENTIFYING GENOMIC REGIONS OF LOW BACKGROUND METHYLATION | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4731791-A2 | METHODS FOR PREDICTING TUMOR CONTENT USING EPIGENETIC SIGNATURES | Flagship Pioneering Innovations VI, LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260015678-A1 | TIERED TESTING FOR HIGH RISK POPULATIONS | HARBINGER HEALTH INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250357009-A1 | MULTI-TIERED TESTING FOR TRACKING DISEASE HETEROGENEITY | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2025-11-20 | — | — | US | disclosed |
| US-20250354211-A1 | METHODS FOR ENRICHING NUCLEIC ACID TARGET SEQUENCES | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4634407-A1 | PHASED SEQUENCING INFORMATION FROM CIRCULATING TUMOR DNA | Flagship Pioneering Innovations VI, LLC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250305064-A1 | PHASED SEQUENCING INFORMATION FROM CIRCULATING TUMOR DNA | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2025-10-02 | — | — | US | disclosed |
| US-20250270650-A1 | METHODS FOR IDENTIFYING GENOMIC REGIONS OF LOW BACKGROUND METHYLATION | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2025-08-28 | — | — | US | disclosed |
| US-20250223652-A1 | TIERED TESTING FOR HIGH RISK POPULATIONS | HARBINGER HEALTH INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250051854-A1 | METHODS FOR PREDICTING TUMOR CONTENT USING EPIGENETIC SIGNATURES | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2025-02-13 | — | — | US | disclosed |
| WO-2024263755-A2 | METHODS FOR PREDICTING TUMOR CONTENT USING EPIGENETIC SIGNATURES | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024129712-A1 | PHASED SEQUENCING INFORMATION FROM CIRCULATING TUMOR DNA | FLAGSHIP PIONEERING INNOVATIONS, VI, LLC (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024064369-A1 | METHODS FOR AMPLIFYING NUCLEIC ACIDS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024064919-A2 | METHODS FOR EPITYPE ENRICHED PCR SCREENING | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024064915-A2 | METHODS FOR ENRICHING NUCLEIC ACID TARGET SEQUENCES | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-03-28 | — | — | WO | disclosed |
| CN-116157519-A | Purification of sulfonated DNA | 精密科学公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-108794408-A | Pyrimidine phenylurea anti-tumor compounds and its preparation method and application | 中国医科大学 | 2018-11-13 | — | — | CN | disclosed |
| CN-1678188-B | Nucleic acid compositions for modulating immune responses | COLEY PHARM GROUP INC | 2012-10-10 | — | — | CN | disclosed |
| CN-1678188-A | Nucleic acid compositions for modulating immune responses | COLEY PHARM GROUP INC (US) | 2005-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260117312-A1 | METHODS FOR IDENTIFYING GENOMIC REGIONS OF LOW BACKGROUND METHYLATION | DNMT3A, DNMT3L, DNMT3B | GAA 3898/4885DPYD 2460/4885MAPT 3414/4885 |
| US-20260015678-A1 | TIERED TESTING FOR HIGH RISK POPULATIONS | DNMT1, BRCA1, DNMT3L | GAA 3866/4885DPYD 2186/4885MAPT 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.